文献速递神经肿瘤

Chaetocin抑制SUV39H1靶向弥漫性中线胶质瘤的干性与致癌网络并与ONC201协同

Chaetocin-mediated SUV39H1 inhibition targets stemness and oncogenic networks of diffuse midline gliomas and synergizes with ONC201.
PubMed 文献 · Neuro Oncol · 2024-01-01

本研究通过对表观遗传酶化合物库筛选,发现chaetocin可选择性抑制患者来源的DIPG细胞增殖并诱导凋亡,延长DIPG异种移植模型生存;其靶点SUV39H1缺失或抑制下调干性及致癌网络,但DRD2信号代偿上调导致耐药,联合DRD2拮抗剂ONC201可协同增强抗肿瘤疗效。

要点

  • Chaetocin选择性降低DIPG细胞增殖并增加凋亡,延长DIPG异种移植模型生存。
  • SUV39H1缺失或抑制下调干性及致癌网络,但DRD2信号代偿上调导致耐药。
  • Chaetocin联合DRD2拮抗剂ONC201协同增强抗肿瘤疗效。

核心结论

  • 靶向SUV39H1-H3K9me3通路及代偿信号环可揭示DIPG细胞的治疗脆弱性。
  • 将靶向SUV39H1的chaetocin与其他药物如ONC201联合可能为有效治疗DIPG提供新策略。

研究设计与样本

  • 对靶向表观遗传酶的化合物进行筛选,以识别患者来源DIPG细胞生长的潜在抑制剂。
  • 开展转录组与基因组图谱分析(包括RNA-seq和CUT&RUN-seq)以及shRNA介导的敲低,评估chaetocin及其靶点SUV39H1对DIPG生长的影响。

主要发现

  • 高通量小分子筛选鉴定出表观遗传化合物chaetocin为DIPG细胞生长的强效阻断剂。
  • Chaetocin处理选择性降低DIPG细胞增殖并增加凋亡,显著延长DIPG异种移植模型生存,同时恢复H3K27me3水平。
  • H3K9甲基转移酶SUV39H1缺失抑制DIPG细胞生长。
  • 转录组与表观基因组分析显示SUV39H1缺失或抑制下调干性及致癌网络(包括生长因子受体信号和干性相关程序),但D2多巴胺受体(DRD2)信号适应性代偿上调导致耐药。
  • Chaetocin与DRD2拮抗剂ONC201联合协同增强抗肿瘤疗效。

临床怎么用

  • 作者认为,将靶向SUV39H1的chaetocin与其他药物如ONC201联合可能为有效治疗DIPG提供新策略。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Diffuse intrinsic pontine gliomas (DIPG/DMG) are devastating pediatric brain tumors with extraordinarily limited treatment options and uniformly fatal prognosis. Histone H3K27M mutation is a common recurrent alteration in DIPG and disrupts epigenetic regulation. We hypothesize that genome-wide H3K27M-induced epigenetic dysregulation makes tumors vulnerable to epigenetic targeting. METHODS: We performed a screen of compounds targeting epigenetic enzymes to identify potential inhibitors for the growth of patient-derived DIPG cells. We further carried out transcriptomic and genomic landscape profiling including RNA-seq and CUT&RUN-seq as well as shRNA-mediated knockdown to assess the effects of chaetocin and SUV39H1, a target of chaetocin, on DIPG growth. RESULTS: High-throughput small-molecule screening identified an epigenetic compound chaetocin as a potent blocker of DIPG cell growth. Chaetocin treatment selectively decreased proliferation and increased apoptosis of DIPG cells and significantly extended survival in DIPG xenograft models, while restoring H3K27me3 levels. Moreover, the loss of H3K9 methyltransferase SUV39H1 inhibited DIPG cell growth. Transcriptomic and epigenomic profiling indicated that SUV39H1 loss or inhibition led to the downregulation of stemness and oncogenic networks including growth factor receptor signaling and stemness-related programs; however, D2 dopamine receptor (DRD2) signaling adaptively underwent compensatory upregulation conferring resistance. Consistently, a combination of chaetocin treatment with a DRD2 antagonist ONC201 synergistically increased the antitumor efficacy. CONCLUSIONS: Our studies reveal a therapeutic vulnerability of DIPG cells through targeting the SUV39H1-H3K9me3 pathway and compensatory signaling loops for treating this devastating disease. Combining SUV39H1-targeting chaetocin with other agents such as ONC201 may offer a new strategy for effective DIPG treatment.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Xin DE, Liao Y, Rao R, et al. Chaetocin-mediated SUV39H1 inhibition targets stemness and oncogenic networks of diffuse midline gliomas and synergizes with ONC201. Neuro Oncol. 2024. PMID: 38011799. doi:10.1093/neuonc/noad222

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。